Description
Seladelpar is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.
Clinically, seladelpar reduces pruritus (itching) and interleukin-31 in people with primary biliary cholangitis. Seladelpar was approved for medical use in the United States in August 2024
LIVDELZI® (seladelpar) capsules, for oral use Initial U.S. Approval: 2024
See full prescribing information: Click Here
Get Access To Livdelzi (seladelpar) In India
In India, access is facilitated through a legally compliant Named Patient Program (NPP), as per guidelines from the Central Drugs Standard Control Organization. This ensures safe and regulated import of the medicine for individual patients. Brand Name “Livdelzi” or Generic Name “seladelpar” can be imported for personal use under “Named Patient Program” treatment in in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla India.. Contact us at support@southdelhipharma.com, southdelhipharma@gmail.com or call/WhatsApp at +91-9891296838 to get access as per norms.
